$CLNN SEC Filings

Filed On	Filing
21 Oct 2026	Form 4: Etherington Robert Dee, Director Granted 55,000 stock option
21 Oct 2026	Form 4: Mortenson Mark, Chief Science Officer Granted 30,000 stock option
21 Oct 2026	Form 4: Brown Morgan R, Chief Financial Officer Granted 20,000 stock option
20 Oct 2026	8-K: Entry into a Material Definitive Agreement Previously, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”) announced (i) on October 5, 2023, a four-year, $45.1 million grant (“the NIH Grant”) fr...
19 Oct 2026	8-K: Other Events NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes
13 Oct 2026	SCHEDULE 13G/A
18 Sep 2026	Form 4: Matlin David J, Director Received 434,451 shares as a grant or award ($1.42M)
18 Sep 2026	Form 4: Etherington Robert Dee, Director Received 15,244 shares as a grant or award ($50K)
18 Sep 2026	Form 4: Mosca Alison, Director Received 198,171 shares as a grant or award ($650K)
16 Sep 2026	FORM 424B5
16 Sep 2026	8-K: Entry into a Material Definitive Agreement; Other Events This Securities Purchase Agreement (this “Agreement”) is dated as of September 15, 2026, between Clene Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its success...
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	Form 4: Kiernan Matthew, Director Granted 3,195 stock option
14 Aug 2026	Form 4: Desai Arjun Jj, Director Granted 3,674 stock option
14 Aug 2026	Form 4: Mosca Alison, Director Granted 4,872 stock option
14 Aug 2026	Form 4: Matlin David J, Director Granted 6,230 stock option
14 Aug 2026	Form 4: Jacobovitz Shalom, Director Granted 4,752 stock option
14 Aug 2026	Form 4: Gay Jonathon, Director Granted 3,794 stock option
14 Aug 2026	Form 4: McLaughlin Vallerie, Director Granted 3,514 stock option
14 Aug 2026	Form 4: Wilcox Reed N, Director Granted 3,514 stock option

Comments